What treatment do you use for stroke prevention in cervical artery dissection?
What is your preferred treatment for stroke prevention in cervical artery dissection?
Join Mednetto vote and see how they answered.
The STOP-CAD trial similarly compared antiplatelet and anticoagulation therapy for extra-cranial dissection, but included all forms of anticoagulation and conducted several subgroup analyses. It found a non-statistical trend favoring anticoagulation, with a statistically significant increase in hemorrhagic risk at 180 days. The trial also demonstrated the benefit of anticoagulation in occlusive dissection, which is a new finding. Subgroup analyses compared dual-antiplatelet to DOACs/VKAs demonstrating a non-statistical trend towards anticoagulation with similar hemorrhage risk, but underpowered to make any conclusion.
In clinical practice, I base the treatment approach on dissection features, the patient’s clinical presentation, and overall hemorrhage risk. For asymptomatic patients without high-risk features (stenosis, occlusion, or thrombus burden), I prefer dual-antiplatelet for at least 3 months, although aspirin mono-therapy is reasonable. For symptomatic patients with high-risk features, I prefer anticoagulation with a DOAC for at least 3 months. For patients with high hemorrhage risk, such as trauma cases, aspirin mono-therapy is typically sufficient. The trauma service can provide guidance if treatment escalation is required.
Regardless of the treatment approach, follow-up vessel imaging at 3 months, combined with clinical correlation, should guide the decision on continuing or de-escalating therapy. Despite more trial data, definitive management for cervical dissection remains open to interpretation, although sub-clinical data continues to favor anticoagulation.
The link below is a useful flowchart on the management of cervical dissection:
I agree with Dr. @Dr. First Last. My approach to stroke prevention (based on insights from the three trials and subgroup analyses) for extracranial dissection is case-based. If there are high-risk features; occlusion, thrombus, ischemic stroke, or distal embolic detection on TCD, I use anticoagulation, usually a DOAC for at least three months (before transitioning to antiplatelet) with repeat imaging. During pregnancy, I use Lovenox. In slightly higher-risk hemorrhage patients, I do start with a heparin drip first before DOAC transitioning. For patients without high-risk features and an extracranial dissection flap not causing occlusion, and without distal microembolic detection on TCD presenting with local symptoms or incidentally found asymptomatic dissection in patients with elevated hemorrhage risk (risks versus benefits), I use dual antiplatelets and repeat imaging in three months before transitioning to single antiplatelet therapy.